Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

415.21 -2.63 (-0.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
69 70 Next >
News headline image
Why Are Amgen (AMGN) Shares Soaring Today
Shares of biotech company Amgen (NASDAQ:AMGN) jumped 6.4% in the afternoon session after the company announced a $650 million investment to expand its US manufacturing network. The investment is aimed... 
Via StockStory
Topics Economy Government Intellectual Property
News headline image
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday? ↗
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat. 
Via Benzinga
Amgen Announces $650M Expansion Of US Manufacturing Network After Trump’s Pharma Tariff Announcement ↗
Via Stocktwits
Topics Government
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Why Drug Stocks Are Celebrating Trump's 100% Pharmaceutical Tariff ↗
Drug stocks are celebrating in the wake of Trump's threat to levy a 100% tariff on pharmaceutical imports starting Wednesday. 
Via Investor's Business Daily
Topics Economy Government World Trade
News headline image
Healthcare Staffing Giant AMN Healthcare Soars Amidst Landmark Drug-Pricing Agreement
New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a... 
Via MarketMinute
Topics Government
News headline image
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing... 
Via MarketMinute
Topics Economy Government World Trade
News headline image
Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. 
Via StockStory
Topics Government
News headline image
Marjorie Taylor Greene Loads Up On Six-Figure Treasury Bill— Diversifies Portfolio With Bitcoin ETF, Tech Stocks ↗
Rep. Marjorie Taylor Greene's latest trades reveal a six-figure Treasury Bill buy, plus new stakes in tech stocks and a Bitcoin ETF. 
Via Benzinga
Topics ETFs
News headline image
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever ↗
Dividend stocks can be a more predictable stream of income for investors. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Program ↗
The announcement from the group coincides with the deadline set by President Trump for 17 pharmaceutical companies to reduce drug prices in the U.S. to the levels paid by other developed countries. 
Via Stocktwits
Topics Government
News headline image
Why the Schwab U.S. Dividend Equity ETF Could Be a Top Choice for Dividend Investors in 2025 ↗
Instead of choosing just one or two stocks, buy a bunch of quality dividend-payers with a single ETF. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
Amgen Expands US Manufacturing Network Amid New Tariff Policy ↗
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network. 
Via Benzinga
Topics Government World Trade
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
The Analyst Verdict: Amgen In The Eyes Of 8 Experts ↗
8 analysts have shared their evaluations of Amgen (NASDAQ: AMGN) during the recent three months, expressing a mix of bullish and bearish perspectives. 
Via Benzinga
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
News headline image
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval ↗
AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results. 
Via Benzinga
News headline image
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron
Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity... 
Via MarketMinute
Topics Economy
News headline image
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Amgen (AMGN) Stock Is Trading Up Today
Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.4% in the afternoon session after a European regulatory body recommended approving its drug, Uplizna, for treating a rare autoimmune disorder. 
Via StockStory
Topics Artificial Intelligence
News headline image
Friday's session: top gainers and losers in the S&P500 index ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
News headline image
Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections
Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle
The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like... 
Via MarketMinute
News headline image
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
News headline image
EMA Backs Amgen Drug For Rare Autoimmune Disorder ↗
European Medicines Agency's panel recommends expanding Amgen's Uplizna to treat IgG4-related disease, with trial data showing reduced flares and higher remission rates. 
Via Benzinga
News headline image
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. 
Via Chartmill
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.